AB0522 Effect of first-line anti-tnf therapy on health related quality of life in patients with ankylosing spondylitis - results from the czech biologics registry attra. (23rd January 2014)
- Record Type:
- Journal Article
- Title:
- AB0522 Effect of first-line anti-tnf therapy on health related quality of life in patients with ankylosing spondylitis - results from the czech biologics registry attra. (23rd January 2014)
- Main Title:
- AB0522 Effect of first-line anti-tnf therapy on health related quality of life in patients with ankylosing spondylitis - results from the czech biologics registry attra
- Authors:
- Forejtova, S.
Závada, J.
Jarosova, K.
Uher, M.
Hejduk, K.
Pavelka, K.
Vencovsky, J. - Abstract:
- Abstract : Objectives: The aim of this study was to describe changes in the Medical Outcomes Study Short Form-36 (SF-36) physical (PCS) and mental (MCS) component summary and domain scores for ankylosing spondylitis (AS) patients enrolled in the ATTRA registry and completing one year of the first-line anti-TNF therapy., SF-36 domain scores of AS patients before and after one year of anti-TNF therapy were compared with age-standardized normative values of the general Czech population. Methods: Only AS patients with available clinical (BASDAI, HAQ) and HRQOL (SF-36) data completing one year of anti-TNF treatment were included in the analyses. Paired Wilcoxon test was used to compare changes in continuous variables with baseline levels. One- sample T test was used to compare age-standardized mean domain scores of AS patients with reportedCzech normative values [1 ]. Numbers are median (5%>95% percentile) if not stated otherwise Results: 535 AS patients with available required data and completing one year of the first-line anti-TNF therapy were identified. In the analyzed sample there were 74% of males, with median age of 37 years (25-75) and median disease duration of 5 years (0-22) at the start of anti-TNF therapy. 23%, 35% and 43%of patients were treated with infliximab, adalimumab, and etanercept, respectively. PCS scores improved from 29 (11-62) to 58 (26-85) at W12 (p<0.001) and to 64 (26-91) at W54 (p<0.001). MCS scores improved from 43 (17-75) to 66 (31-87) at W12Abstract : Objectives: The aim of this study was to describe changes in the Medical Outcomes Study Short Form-36 (SF-36) physical (PCS) and mental (MCS) component summary and domain scores for ankylosing spondylitis (AS) patients enrolled in the ATTRA registry and completing one year of the first-line anti-TNF therapy., SF-36 domain scores of AS patients before and after one year of anti-TNF therapy were compared with age-standardized normative values of the general Czech population. Methods: Only AS patients with available clinical (BASDAI, HAQ) and HRQOL (SF-36) data completing one year of anti-TNF treatment were included in the analyses. Paired Wilcoxon test was used to compare changes in continuous variables with baseline levels. One- sample T test was used to compare age-standardized mean domain scores of AS patients with reportedCzech normative values [1 ]. Numbers are median (5%>95% percentile) if not stated otherwise Results: 535 AS patients with available required data and completing one year of the first-line anti-TNF therapy were identified. In the analyzed sample there were 74% of males, with median age of 37 years (25-75) and median disease duration of 5 years (0-22) at the start of anti-TNF therapy. 23%, 35% and 43%of patients were treated with infliximab, adalimumab, and etanercept, respectively. PCS scores improved from 29 (11-62) to 58 (26-85) at W12 (p<0.001) and to 64 (26-91) at W54 (p<0.001). MCS scores improved from 43 (17-75) to 66 (31-87) at W12 (p<0.001) and to 70 (31-91) at W54 (p<0.001). Conclusions: In this cohort of AS patients completing one year of the first-line anti-TNF therapy clinically meaningful and statistically significant improvements were observed in all SF-36 domains. In 4 domains (vitality, social functioning, role emotional, and mental health) the AS patients reached normative values of the Czech general population. . References: References: Sobotník Z. [Experiences with the application of preliminary Czech version of the questionary SF36]. Zdravotnictví v ČR 1 – 2 / 1998, str. 50 – 54 Acknowledgements: Supported by project 00023728 from Ministry of Health in the Czech Republic Disclosure of Interest: None Declared … (more)
- Is Part Of:
- Annals of the rheumatic diseases. Volume 72:Supplement 3(2013)
- Journal:
- Annals of the rheumatic diseases
- Issue:
- Volume 72:Supplement 3(2013)
- Issue Display:
- Volume 72, Issue 3 (2013)
- Year:
- 2013
- Volume:
- 72
- Issue:
- 3
- Issue Sort Value:
- 2013-0072-0003-0000
- Page Start:
- A948
- Page End:
- A949
- Publication Date:
- 2014-01-23
- Subjects:
- Rheumatism -- Periodicals
616.723005 - Journal URLs:
- http://ard.bmjjournals.com/ ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=149&action=archive ↗
http://www.bmj.com/archive ↗
http://gateway.ovid.com/server3/ovidweb.cgi?T=JS&MODE=ovid&D=ovft&PAGE=titles&SEARCH=annals+of+the+rheumatic+diseases.tj&NEWS=N ↗ - DOI:
- 10.1136/annrheumdis-2013-eular.2844 ↗
- Languages:
- English
- ISSNs:
- 0003-4967
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19893.xml